Open access
Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis
H. Mian
M. Faisal
Tie-Ning Chen
R. Brazauskas
Temitope Oloyede
Nausheen Ahmed
Aimaz Afrough
Larry D. Anderson
Rahul Banerjee
Jesus G. Berdeja
A. Bidikian
Jakob Devos
Binod Dhakal
Ajoy L. Dias
Danai Dima
Yvonne A. Efebera
Lohith Gowda
Doris K. Hansen
H. Hashmi
H. Landau
L. Lekakis
A. Mirza
Ravi K. Narra
Krina K. Patel
A. Rosko
Mark A. Schroeder
S. Sidana
S. Usmani
Marcelo C. Pasquini
T. Nishihori
O. Akhtar
M. Mohan
Medicine
Abstract
Ciltacabtagene autoleucel (cilta‐cel), an anti–B‐cell maturation antigen (BCMA) chimeric antigen receptor T‐cell (CAR‐T) therapy, is approved for relapsed/refractory multiple myeloma (RRMM).